Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI).

Bernadett SzabadosMariano Ponz-SarviséRobson MachadoDiego SaldanaEdward E Kadel Romain BanchereauFanny BouquetMarius GarmhausenThomas Powles Carsten Schrödernull null

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Contemporary RWD including FoundationOne CGP can be used to characterize outcomes in real-world patients according to biomarkers beyond PD-L1. A validated, novel clinico-genomic BIPI demonstrated satisfactory prognostic performance for OS in patients with mUC receiving front-line ICI therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
healthcare
primary care
prognostic factors
genome wide
stem cells
type diabetes
metabolic syndrome
adipose tissue
patient reported outcomes
weight loss
urinary tract